IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model

Front Immunol. 2022 Apr 21:13:884827. doi: 10.3389/fimmu.2022.884827. eCollection 2022.

Abstract

The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melanoma model. We found that melanoma cells exposed to γ-irradiation or lysis combined with UV-irradiation (LyUV) provided better protection against tumor challenge than lysis only or cells exposed to UV-irradiation. Furthermore, we found that the immunoregulatory cytokine, IL-27 enhanced protection against tumor growth in a dose-dependent manner when combined with either LyUV or γ-irradiated whole tumor cell vaccine preparations. Taken together, this data supports the use of LyUV as a potential protocol for developing whole tumor cell prophylactic cancer vaccines. We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or γ-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model.

Keywords: IL-27; adjuvant; cancer vaccine; cell death; melanoma; prophylactic.

MeSH terms

  • Animals
  • Cancer Vaccines* / therapeutic use
  • Disease Models, Animal
  • Interleukin-27* / therapeutic use
  • Melanoma* / prevention & control
  • Melanoma* / therapy
  • Mice

Substances

  • Cancer Vaccines
  • Interleukin-27